Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Trend Micro Inc.

Start price
Target price
Perf. (%)
€51.30
16.01.24
-
16.01.25
6.63%
15.02.24

buy
Trend Micro Inc.

Start price
Target price
Perf. (%)
€51.30
16.01.24
-
16.01.25
6.63%
15.02.24

buy
Trend Micro Inc.

Start price
Target price
Perf. (%)
€51.30
16.01.24
-
16.01.25
6.63%
15.02.24

buy
Trend Micro Inc.

Start price
Target price
Perf. (%)
€51.30
16.01.24
-
16.01.25
6.63%
15.02.24

buy
SGL Carbon SE

Start price
Target price
Perf. (%)
€6.51
10.01.24
€0.000
10.01.25
-9.38%
20.01.24

Higher EBIT margin than peer group
EBIT growth >5% per year expected
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
buy
Seres Therapeutics Inc

Start price
Target price
Perf. (%)
€1.32
09.01.24
-
09.01.25
-6.06%
20.01.24

Could be worthwhile Investment >10% per year
buy
Mersana Therapeutics

Start price
Target price
Perf. (%)
€1.99
07.01.24
-
07.01.25
22.24%
13.05.24

Could be worthwhile Investment >10% per year
buy
Hallador Energy Company

Start price
Target price
Perf. (%)
€8.35
06.01.24
-
06.01.25
-4.19%
20.01.24

Could be worthwhile Investment >10% per year
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€2.64
28.12.23
-
28.12.24
-9.11%
06.01.24

Risky Investment
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€2.60
27.12.23
-
27.12.24
12.33%
21.01.24

Could be very worthwhile Investment >20% year
buy
Mersana Therapeutics

Start price
Target price
Perf. (%)
€2.00
27.12.23
-
27.12.24
-0.65%
07.01.24

Could be worthwhile Investment >10% per year
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€2.60
27.12.23
€3.00
27.12.24
13.68%
28.12.23

Could be worthwhile Investment >10% per year
Good culture
Capable Management
Few uniques
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€43.80
26.12.23
-
26.12.24
32.42%
13.05.24

Could be very worthwhile Investment >20% year
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€43.80
24.12.23
€100.00
28.02.26
73.52%
25.01.24

Could be very worthwhile Investment >20% year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.20
24.12.23
-
24.12.24
1.36%
06.01.24

Could be worthwhile Investment >10% per year
Enlivex Therapeutics Ltd.

Start price
Target price
Perf. (%)
€2.90
22.12.23
-
22.12.24
-17.24%
26.12.23

Could be worthwhile Investment >10% per year
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€2.09
22.12.23
-
22.12.24
9.11%
23.12.23

Could be worthwhile Investment >10% per year
Fortuna Silver Mines Inc.

Start price
Target price
Perf. (%)
€3.51
19.12.23
-
19.12.24
-6.26%
18.01.24

Could be very worthwhile Investment >20% year
EBIT growth > 30% per year expected
Rising EBIT margin expected
Revenue growth > 30% per year expected
First Majestic Silver Corp.

Start price
Target price
Perf. (%)
€5.58
19.12.23
-
19.12.24
-20.83%
18.01.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€5.22
15.12.23
-
15.12.24
56.32%
31.01.24

Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.84
14.12.23
-
14.12.24
23.78%
23.12.23

Could be worthwhile Investment >10% per year
buy
Perion Network Ltd.

Start price
Target price
Perf. (%)
€29.70
13.12.23
€40.00
13.12.24
-6.67%
23.12.23

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
buy
Varonis Systems Inc.

Start price
Target price
Perf. (%)
€41.30
13.12.23
-
13.12.24
13.08%
15.02.24

buy
flatexDEGIRO AG

Start price
Target price
Perf. (%)
€10.85
12.12.23
-
12.12.24
-6.69%
31.01.24

Marathon Digital Holdings

Start price
Target price
Perf. (%)
€14.66
11.12.23
€11.00
11.12.24
39.50%
20.03.24

High dividend yield expected
Small Risks for its business
High valuation
Little Investments for future growth